BiotechTube
Home/Galecto/Dr. Bertil Lindmark
DB

Dr. Bertil Lindmark

Chief Medical Officer

Galecto

Therapeutic Areas

FibrosisOncology

Galecto Pipeline

DrugIndicationPhase
GB1211MASH with liver fibrosisPhase 2b
TD139Idiopathic Pulmonary Fibrosis (IPF)Phase 2/3
GB2064MyelofibrosisPhase 2

Leadership Team at Galecto

DH
Dr. Hans Schambye
Chief Executive Officer
DS
Dr. Steen Lisby
Chief Scientific Officer
DJ
Dr. Jonathan Freve
Chief Financial Officer
DA
Dr. Allen Baharaff
Chief Business Officer
DJ
Dr. J. Donald deBethizy
Chairman of the Board
DL
Dr. Laurie Keating
Board Director
View full Galecto profile